Anecortave, a synthetic cortisone, has been shown to have antiangiogenic properties that have been established in multiple experimental models of angiogenesis. Anecortave is under investigation to treat exudative age-related macular degeneration (AMD). Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Anecortave is the active ingredient of these drugs: